Cambridge-based Uniqsis reported significant first year developments culminating with the first of its FlowSynâ„¢ Continuous Flow Reactor systems installed in pharmaceutical development laboratories.
Managing Director Martyn Fordham said “It’s been an incredibly busy but rewarding year. The development team took FlowSyn from concept design and first prototype phases through to beta trial systems for pilot customers and now to the manufacture of fully standards-tested production models, and all in less than 12 months.†Dr Mark Ladlow, a leading authority on flow chemistry has also joined the company as Chief Scientific Officer.
Mark was until recently head of the GSK Cambridge Technology Laboratory based within the University of Cambridge. New distributors for FlowSyn have been appointed in France, USA, Italy and India.
Product directory
